Predicting blood clots in ICU patients with a blood test
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been admitted to an intensive care unit (ICU) in the past 24 hours.
- Your doctors expect you to be in the ICU for more than 2 days from now.
- You are not on a high dose of blood thinners (like enoxaparin).
- You are not on or about to need a heart-lung machine (ECMO).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This trial tests a new computer tool that helps doctors decide whether you likely have a blood clot in your leg or lung. If you have symptoms and are not already on blood thinners, you may be able to join.
This study looks at people with interstitial lung disease (a lung scarring condition) who have new or worsening symptoms that might be caused by a blood clot in the lungs (pulmonary embolism). Doctors want to find better ways to predict which patients actually have a clot, which could lead to earlier and more accurate treatment.
This study focuses on diagnosing deep-vein thrombosis (DVT, blood clots in the leg) early in people who are very ill in the ICU. It aims to test an approach to better detect clots sooner, which could help prevent complications.
This trial compares three different blood thinners (heparin, argatroban, and enoxaparin) used during ECMO support. It aims to find the safest and most effective way to prevent blood clots while on ECMO.
This study looks at how a common blood thinner (enoxaparin) is processed in the body of ICU patients with kidney failure, including those on dialysis. The goal is to make sure the dose is safe and effective for preventing blood clots in this fragile group.
Hear when a new Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.